The Hindu Business Line : Natco bags award for cancer drug research

AFTER bagging the Department of Scientific and Industrial Research (DSIR) annual award for its research & development efforts, Natco Pharma Ltd (NPL), the city-based integrated pharmaceutical company, has now won the award in `Best technology development in R&D' from the Federation of Andhra Pradesh Chamber of Commerce and Industry (FAPCCI).

In a press release, NPL said it was chosen for the FAPCCI annual award for its efforts made in R&D, especially in the successful development and commercialisation of an innovative technology for the manufacture of Imatinib Mesylate, an anti-cancer drug.

According to the company, the award would be presented at the ensuing annual function and awards distribution of FAPCCI, the date of which was yet to be announced. Natco, the manufacturer of finished dosage forms, active pharmaceutical ingredients, advanced intermediates and custom-manufactured speciality chemicals, has applied for an international patent for the method of manufacture of Imatinib Mesylate.

Article E-Mail :: Comment :: Syndication

Stories in this Section
Linc Pen to manufacture Mitsubishi products

No plans to set up unit in US now: Elgi

Novartis receives exclusive marketing rights for Glivec

Residency Hotel to offer service apartments

LG Pune factory to be made export hub

Handicrafts Export Corpn presents dividend cheque

Apollo Hospitals brings out CD on laparoscopic surgery

Natco to challenge grant of exclusive rights to Novartis cancer drug

Norms tightened for external borrowings — End-use conditions read tough

Corporates yet to heed RBI advice on hedging exposures

BPL to raise $100 m from external borrowing for turnaround